#PortfolioNews | Memo Therapeutics partners with CSL to advance recombinant polyclonal IgG, validating its DROPZYLLA® platform. 🚀🧬
👉 buff.ly/uCOUhUh
#YsiosPortfolio
0
0
0
0
Hashtag
#PortfolioNews
Advertisement · 728 × 90
#rukis #redlantern #graysonreed #furry #art #furryart #painting #illustration #furrysfw #furrynovel #furrynovels #lutherdenholme #anthro #wip #novels #lgbt #furrylgbt #gay #hearttheft #darcy #Isidor #furrylgbt #OTBP #Shivah #OFFTHEBEATENPATH #illicitalliance #darcy #portfolionews
2
0
0
0
Journal of Medical Economics study shows significant cost savings via MAF Test® – guided adjuvant bisphosphonate therapy for early-stage breast cancer
#PortfolioNews I Study shows that #MAFTest® developed by our #portfolio company #Ibiomotion may save €105M in early #breast #cancer care.
🔗 Press release - buff.ly/8pAhrip
📄 Full publication here: lnkd.in/d3aUWmpp
#Oncology #HealthEconomics #BreastCancer
1
0
0
0
VarmX partners with CSL in a strategic collaboration and option agreement to develop novel investigational coagulation treatment
📢 #PortfolioNews | Excited to share the strategic deal of our #portfolio company #VarmX with #CSL 💊
🔹Up to $2.2B incl. $117m upfront & milestones
🔹Global Phase 3 of VMX-C001 fully funded
🌍Step closer to market for a major unmet need
👉 buff.ly/aO4iHwV
#YsiosPortfolio #vc
3
0
0
0
#PortfolioNews I MAF Test® now adopted in top #Spanish hospitals to personalize early-stage #breast #cancer treatment. A major step for our #portfolio company #Inbiomotion !
👉 Full details here - buff.ly/aT4nwud
#BreastCancer #Oncology #PortfolioNews #MAFTest
1
0
0
0
#PortfolioNews | Proud to join the $135M Series B of our #portfolio company #SpliceBio, the largest round ever raised by a Spanish biotech 🚀
🧬 Advance SB-007 for #StargardtDisease
🔬Expand #GeneticMedicine pipeline
👉 buff.ly/jey8g9O
#VC #Biotech #Innovation #ProteinSplicing
3
0
1
0
We are excited to support Adaptam’s mission to pioneer a new era of cancer #immunotherapy!
Learn more about Adaptam at: www.adaptamtx.com
#portfolionews #venturecapital #biotech #lifesciences #oncology #cancer #tumor #macrophages #glycobiology #glycans
0
0
0
0
#PortfolioNews | #SparingVision receives #FDA support to launch Phase II trial of SPVN06 in #GeographicAtrophy
🎯 #GA is an advanced form of dry age-related macular degeneration (dAMD) that leads to progressive and irreversible vision loss
👉 buff.ly/m0BlGti
#GeneTherapy
0
0
0
0
#PortfolioNews I Our #portfolio company #Xeltis passes #EIC evaluation for potential €10M funding
🎯Developing regenerative implants to transform vascular surgery through natural tissue regeneration.
👉 buff.ly/rl7BP3W
#vc #innovation #dialysis
1
0
0
0
#PortfolioNews I We’re excited to share that our #portfolio company #Anacond Biomed has enrolled the first U.S. patient in its ATHENA trial.
🎯 Developing next-generation #neurothrombectomy devices for acute ischemic #stroke
👉 buff.ly/vXEDmrK
#vc #Spain #Medtech
2
0
0
0
#PortfolioNews | SpliceBio doses the first patient in the Phase 1/2 ASTRA study of SB-007, the first dual AAV #GeneTherapy for #StargardtDisease!
🎯 Showcasing the power of #ProteinSplicing to tackle diseases caused by #LargeGenes mutations.
👉 buff.ly/HvB3bPR
#VC
2
0
0
0
#PortfolioNews | Our #quoted company Mineralys Therapeutics (Nasdaq: #MLYS) reports #positive Phase 3 & 2 results for #lorundrostat in #hypertension & announces a $250M #PublicOffering to advance R&D!
👉 buff.ly/qeyUu5K
👉 buff.ly/g18zKmA
#ClinicalTrials
2
0
0
0
#PortfolioNews | NorthSea Therapeutics reports positive results from the Phase 2b ICONA trial of #Icosabutate in #MASH, published in the Journal of Hepatology!
📢 Read more: 👉 buff.ly/49eOq1j
📑 Full publication buff.ly/jZ9cXPW
#vc #fibrosis #metabolic
1
0
0
0
#PortfolioNews I Our portfolio company #Minoryx Therapeutics has dosed the first patient in the Phase 2a TREE study of #leriglitazone for #RettSyndrome! 🧠
🗓️ Results expected in H12026
👉 buff.ly/NycHUxI
#CNS #RareDisease #vc
1
0
0
0
#PortfolioNews | Adcendo receives #FDA clearance for Phase I trial of ADCE-T02
🎯 First-in-class #ADC targeting Tissue Factor in #SolidTumors.
🌍 Now recruiting in #Australia with #US expansion soon!
👉 Read more https://buff.ly/3Dc92qj
#Onclogy #vc
1
0
0
0
#PortfolioNews | Our #portfolio company Neurona Therapeutics plans Phase3 trial in H2 2025 for NRTX-1001, a #celltherapy for drug-resistant #epilepsy.
🔬 Encouraging early data: Up to 97% seizure reduction with no cognitive impairment
📢 Read more: https://buff.ly/3Dh9kfv
#VC
1
1
0
0
#PortfolioNews I NorthSea Therapeutics strengthens leadership & advances metabolic, cholestatic & fibrotic disease therapies.
🔬 Key trials ahead!
👉 https://buff.ly/3Quv4HV
#vc #MetabolicDiseases
0
0
0
0
#PortfolioNews I Our #portfolio company ONA Therapeutics strengthens leadership to accelerate first-in-class #ADCs targeting resistant #cancer cells & advancing toward #clinical development.
📢 Read more here https://buff.ly/4gK9vh3
#Oncology #Biotech #Pharma #YsiosPortfolio
2
0
0
0
#PortfolioNews I Our #quoted #portfolio company #Mineralys #MLYS completed Enrollment in Explore-CKD Phase 2 Trial of #Lorundrostat for the Treatment of #Hypertension in Subjects with Stage 2 to 3b chronic kidney disease #CKD and #Albuminuria
👉 https://buff.ly/4gqM4t2
#vc #ClinicalTrials
1
0
0
0
Minoryx announces positive results for leriglitazone in the pivotal Ph2/3 trial for pediatric #cALD, a rare and life-threatening neurodegenerative disease. Minoryx plans to submit an EU marketing authorization application by mid 2025.
#portfolionews #biotech #CNS
www.minoryx.com/media/lerigl...
3
0
0
0
#PortfolioNews I We're proud to share that we have joined the oversubscribed $135M Series B financing of our #portfolio company #Adcendo👏
🎯Developing breakthrough #ADCs, for the #treatment of underserved #cancers
👉Full details buff.ly/3Z3JfYm
#vc #oncology #Innovation #biotech #Europe #investment
1
0
0
0
#PortfolioNews I Exciting news from AELIX Therapeutics! 🌍 Their HIV vaccine has been acquired by Gilead Sciences, a global leader in HIV research and innovation. 🔬
🎯 Committed to fostering the growth of the Spanish biotech ecosystem and driving positive societal impact.
👉 buff.ly/3OnAUtt
2
1
0
0